Tecentriq and Zepzelca combination approved as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC).
The combination creates the 4th largest US wafer fabrication equipment supplier, targeting an expanded $5 billion market.
The approval of the twice-daily pill remibrutinib positions the company to challenge injectable treatments in a multi-billion dollar market.
Precious metal outpaces gold as shrinking stockpiles and soaring industrial demand fuel a powerful market rally.
Final regulatory hurdle cleared for the all-stock transaction, paving the way for an October 20 closing and a major expansion into Texas.
Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.
Shares fall despite strong Q3 sales, as expiring EV tax credits and valuation concerns spook investors.
Proposed 'OBBBA' legislation would hike tax credits for new domestic chip plants to 35%, aiming to accelerate 'Made in America' initiatives.